Lowenstein Sandler represented Catalyst Investors and its portfolio company, RepTrak Holdings, Inc. in the transaction. Periscope Equity, a Chicago-based private equity firm specializing in founder-led, technology-enabled...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Indorama Ventures in the transaction. Indorama Ventures (BKK: IVL), a global leader in sustainable chemicals, has entered into an agreement by its Indovinya...
You must be a Standard 1 Year member to access this content.
Skadden is advising Revance Therapeutics, while Kirkland & Ellis and Lowenstein Sandler are advising Crown Laboratories on the deal. Crown Laboratories, Inc., a privately held, global...
You must be a Standard 1 Year member to access this content.
Lowenstein represented First Wave BioPharma, Inc. in the transaction. First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Timber Pharmaceuticals, Inc. in the transaction. Timber Pharmaceuticals, Inc. (NYSE: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Coya Therapeutics in the transaction. Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company, announced a development-and-license deal with Dr. Reddy’s Laboratories for its...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented First Wave BioPharma, Inc. in the transaction. First Wave BioPharma, Inc., (NASDAQ:FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Big Health in the transaction. Big Health, the leading provider of non-drug digital treatments for mental health, announced the acquisition of Limbix, creators...
You must be a Standard 1 Year member to access this content.
Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz advised Entegris, while Lowenstein Sandler advised Infineum on the deal. Infineum and Entegris, Inc. (NASDAQ: ENTG) have entered into a definitive agreement...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Crown Laboratories in the transaction. Crown Laboratories, Inc. (“Crown”), a leading, fully integrated global skincare company, announced its agreement with Eclipse MedCorp LLC,...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Wynnchurch Capital in the transaction. Wynnchurch Capital, L.P. (“Wynnchurch”), a leading middle market private equity firm, executed its investment in Premier Franchise Management...
You must be a Standard 1 Year member to access this content.
